Mechanistic role of the IL-1β/c-Fos/NFATc1 signaling axis in echinococcal infection-promoted osteoclast differentiation and activation in pathological osteolysis: a prospective controlled trial Authors: Yelinaer Ayiheng, Wuluhan Mahan, Zengru Xie Published: 2025 ABSTRACT BackgroundEffective therapies remain elusive for devastating osteolysis in osseous echinococcosis, thus necessitating mechanistic exploration. To elucidate the molecular mechanism by which echinococcal infection promotes osteoclast differentiation and activation via the IL-1β/c-Fos/NFATc1 signaling axis in pathological osteolysis of osseous echinococcosis.MethodsRetrospective RT-qPCR analysis quantified mRNA expression of osteoclastogenesis-associated inflammatory factors (TNF-α, IL-1β, IL-6, IL-8) in bone cyst tissues from 21 osseous echinococcosis patients versus histologically normal bone adjacent to tumors in 21 matched bone tumor controls. Murine RAW 264.7 monocytes/macrophages were divided into: (i) Untreated control; (ii) Osteoclast induction (100 ng/mL RANKL + 25 ng/mL M-CSF); (iii-v) Induction + hydatid antigen B (25/50/75 ng/mL); (vi) Induction + antigen B (75 ng/mL) + IL-1β antagonist (canakinumab, 10 ng/mL). TRAP staining identified osteoclasts (≥ 3 nuclei), with positive cell percentage calculated across ≥ 5 random fields. ELISA measured cytokine levels in supernatants; Western blot quantified c-Fos, NFATc1, Cathepsin K, and MMP9 expression.ResultsBone cyst tissues exhibited elevated TNF-α, IL-1β, IL-6, and IL-8 mRNA versus controls (P < 0.05). Antigen B (25–75 ng/mL) dose-dependently increased TRAP⁺ cells and inflammatory cytokines versus induction group (P < 0.05). c-Fos, NFATc1, Cathepsin K, and MMP9 were upregulated in induction and antigen B (75 ng/mL) groups versus control (P < 0.05), with further elevation in antigen B (75 ng/mL) group versus induction (P < 0.05). Canakinumab reversed these protein increases versus antigen B (75 ng/mL) group (P < 0.05).ConclusionEchinococcal infection promotes pathological osteoclastogenesis and osteolysis through IL-1β/c-Fos/NFATc1 signaling activation. Cystic echinococcosis (CE) is a zoonotic infection caused by the larval stage of Echinococcus granulosus (E. granulosus) sensu lato species complex, including E. granulosus sensu stricto, E. felidis, E. equinus, E. ortleppi, and E. canadensis.With the exception of Antarctica, CE occurs globally and is highly endemic in the Mediterranean Basin, Middle East, Central Asia, China, the Russian Federation, and regions of northern and eastern Africa [1]. CE lesions most frequently develop in the liver (70%) and lungs (20%), though virtually any anatomical site may be affected (spleen, kidneys, heart, central nervous system, bones, etc.). It has been reported that osseous CE accounts for an estimated 0.5%–4% of all CE cases (Monge-Maillo & Lopez-Velez, 2023). [2]. This skeletal manifestation typically involves a single bone, with the spine (40%–50%) representing the most common site, followed by the pelvis (20%–25%), long bones including the femur (15%) and tibia (10%), and less frequently the skull, sternum, scapulae, and phalanges,with a very small number of cases reported in multiple bones [3]. Osseous CE causes severe disability due to its destructive growth pattern that mimics locally aggressive bone lesions [4]. In China, CE is distributed across more than ten provinces in the western, central, eastern, and northeastern regions, with highest endemicity in Xinjiang, Inner Mongolia, Qinghai, and Gansu [5]. Osseous hydatid cysts predominantly develop in vascular spongy bone and the metaphyseal regions of long bones. Within the trabecular bone matrix, multiple CE cysts form interconnected tunnels resembling a “rat-bite” or “moth-eaten” radiographic pattern, frequently leading to pathological fractures. Histopathologically, these lesions exhibit cancer-like invasive growth characteristics without neo-osteogenesis. The cysts lack a fibrous capsule (laminated ectocyst) and demonstrate exogenous expansion; rupture results in leakage of cyst fluid, causing osteolytic destruction. Progressive cyst enlargement directly activates osteoclasts, ultimately leading to the disruption of cortical bone or articular cartilage, pathological fractures or dislocations, and secondary cyst formation in surrounding soft tissues. This is often accompanied by neurological compromise, joint infections, and fistula formation, resulting in high rates of functional impairment [6–9]. Currently, no satisfactory pharmacotherapy exists for osseous echinococcosis. Surgical intervention remains the primary therapeutic approach, typically combined with systemic albendazole therapy [2, 10]. The rigidity of bone tissue, compounded by extensive destruction of osseous and/or periarticular soft tissues from cyst dissemination, renders surgery technically challenging. Intraoperative containment to prevent parasitic dissemination into surrounding structures is critical. However, due to the infiltrative nature of the infection, complete parasite eradication cannot be guaranteed surgically, resulting in recurrence rates as high as 48% [11].The high recurrence and severe morbidity underscore the urgent need to elucidate the underlying pathogenic mechanisms, which is a prerequisite for developing novel non-surgical therapeutic strategies. Adjuvant radiation therapy significantly improves patient outcomes and substantially reduces the risk of recurrence [12]. Novel therapeutic approaches remain imperative for this disease. Given the central role of osteoclasts in bone destruction, we focused on the signaling pathways that drive their aberrant activation.Proinflammatory cytokines—including TNF-α, IL-1β, IL-6, and IL-8—activate osteoclast precursor differentiation into osteoclasts (OCs) [13]. In this study, we conducted a retrospective analysis of osteoclastogenic inflammatory factor expression in surgically obtained bone cyst tissues from 21 osseous CE patients treated in our orthopedic department, compared with control samples of histologically normal bone tissue adjacent to tumors from 21 matched bone tumor patients (archived in our pathology department). Furthermore, to establish a direct causal relationship and dissect the molecular mechanism,murine monocyte/macrophage RAW 264.7 cells were stimulated in vitro with hydatid antigen B protein, with subsequent intervention using the IL-1β antagonist canakinumab. This experimental approach aims to elucidate the molecular mechanisms by which the IL-1β/c-Fos/NFATc1 signaling axis mediates osteoclast differentiation and activation during pathological osteolysis in hydatid infection. Experimental materials and methods Experimental material The murine monocyte/macrophage RAW 264.7 cell line was procured from Procell Life Science & Technology Co., Ltd. (Wuhan, China). RNA extraction was performed using the RNAprep Pure Tissue Total RNA Kit (Cat# DP431; TIANGEN Biotech, Beijing). Complementary DNA synthesis utilized the FastKing gDNA Dispelling RT SuperMix (Cat# KR116; TIANGEN). Quantitative PCR analysis employed FastFire qPCR PreMix (SYBR Green) (Cat# FP207; TIANGEN). Hydatid antigen B protein (Cat# YDYM007; Yuduo Bio, Shanghai) and the IL-1β antagonist canakinumab (Cat# Ab170512; Aladdin Biochemical Technology, Shanghai) were commercially sourced. Primary antibodies included: anti-c-Fos monoclonal antibody (Cat# MA5-15,055), anti-NFATc1 monoclonal antibody (Cat# MA5-32,686), anti-Cathepsin K polyclonal antibody (Cat# PA5-14,270), anti-MMP9 polyclonal antibody (Cat# PA5-13,199), and anti-GAPDH monoclonal antibody (Cat# 39–8600). Secondary detection used HRP-conjugated goat anti-rabbit IgG (Cat# 31,460) – all antibodies obtained from Thermo Fisher Scientific (Waltham, MA, USA). Methodologies Clinical patient samples A retrospective analysis was conducted on 21 histopathologically confirmed bone cyst tissue specimens obtained via surgical biopsy from osseous CE patients treated in our orthopedic department between January 2015 and December 2024, with 21 matched control samples of histologically normal bone tissue adjacent to tumors sourced from bone tumor patients in our pathology department. Differential diagnosis distinguishing bone tumors from osseous CE was established through comprehensive assessment of detailed patient histories, clinical symptomatology, multimodal imaging [X-ray, computed tomography (CT), and magnetic resonance imaging (MRI)], and serological immunogold analysis measuring serum echinococcal antibody (Ab) levels, with patient clinical characteristics detailed in Table 1.Table 1Clinical Information for Patients with bone hydatid diseaseInformationSex(n)21male12female9Age (years, mean ± standard deviation) (range)40.7 ± 10.1(28–53)Infected bone siteClavicle2Femur2Ilium8Rib3Sacrum2Vertebra4Disease Duration, years (Mean ± SD)3.5 ± 1.7 Table 1Clinical Information for Patients with bone hydatid diseaseInformationSex(n)21male12female9Age (years, mean ± standard deviation) (range)40.7 ± 10.1(28–53)Infected bone siteClavicle2Femur2Ilium8Rib3Sacrum2Vertebra4Disease Duration, years (Mean ± SD)3.5 ± 1.7 Clinical Information for Patients with bone hydatid disease RT-qPCR analysis Trizol reagent was added to the bone tissue samples at a ratio of 1 ml per mg of tissue. The mixture was homogenized in a frozen tissue homogenizer with liquid nitrogen to obtain a tissue homogenate. Total RNA was extracted using the RNAprep Pure Kit for Animal Tissues. First-strand cDNA was synthesized from the extracted RNA by reverse transcription using the FastKing cDNA First Strand Synthesis Kit (with gDNase). RT-qPCR was performed with the FastFire Fast qPCR Premix (SYBR Green). The amplification primers used for RT-qPCR are listed in Table 2.Table 2Sequences of oligonucleotide primers used for RT-qPCRPrimer NameSequence (5’ → 3’)TNF-α ForwardGACGCCACATCCCCTGACATNF-α ReverseCGAGGAGGCGCTCCCCAAGAIL-1β ForwardGTTCTTTGAAGCTGATGGCCIL-1β ReverseGTTGTTGTGGCCATGGACAAIL-6 ForwardCCAGGAGAAGATTCCAAAGAIL-6 ReverseCCTGAGAAAGGAGACATGTAIL-8 ForwardGTTTTTGAAGAGGGCTGAGAIL-8 ReverseGGGTTGCCAGATGCAATACGAPDH ForwardGTCACCAGGGCTGCTTTTAGAPDH ReverseCAAGGCTGAGAACGGGAAGC Table 2Sequences of oligonucleotide primers used for RT-qPCRPrimer NameSequence (5’ → 3’)TNF-α ForwardGACGCCACATCCCCTGACATNF-α ReverseCGAGGAGGCGCTCCCCAAGAIL-1β ForwardGTTCTTTGAAGCTGATGGCCIL-1β ReverseGTTGTTGTGGCCATGGACAAIL-6 ForwardCCAGGAGAAGATTCCAAAGAIL-6 ReverseCCTGAGAAAGGAGACATGTAIL-8 ForwardGTTTTTGAAGAGGGCTGAGAIL-8 ReverseGGGTTGCCAGATGCAATACGAPDH ForwardGTCACCAGGGCTGCTTTTAGAPDH ReverseCAAGGCTGAGAACGGGAAGC Sequences of oligonucleotide primers used for RT-qPCR Cell culture The murine monocyte/macrophage RAW 264.7 cell line was maintained in complete DMEM supplemented with 10% fetal bovine serum and 10 U/ml penicillin–streptomycin under standard culture conditions (37 °C, 5% CO₂, humidified atmosphere). Cellular experimental groupings and treatments For experimental interventions, cells were divided into six groups: (i) Control group: basal culture without treatment; (ii) Osteoclastogenesis induction group: continuous 9-day stimulation with 100 ng/ml RANKL and 25 ng/ml macrophage colony-stimulating factor (M-CSF) to drive osteoclast differentiation [14]; (iii) Induction + Hydatid antigen B (25 ng/ml) group: co-treatment with RANKL/M-CSF plus 25 ng/ml hydatid antigen B protein for 9 days; (iv) Induction + Hydatid antigen B (50 ng/ml) group: co-treatment with RANKL/M-CSF plus 50 ng/ml antigen B; (v) Induction + Hydatid antigen B (75 ng/ml) group: co-treatment with RANKL/M-CSF plus 75 ng/ml antigen B; (vi) Induction + Hydatid antigen B (75 ng/ml) + IL-1β antagonist group: co-treatment with RANKL/M-CSF, 75 ng/ml antigen B, and 10 ng/ml canakinumab (anti-IL-1β monoclonal antibody) for 9 days [15]. All induction protocols aimed to promote osteoclast differentiation.The experimental groups and treatments are summarized in the flowchart (Fig. 1). Fig. 1Flowchart of experimental group design and treatment protocol Flowchart of experimental group design and treatment protocol TRAP immunostaining in bone repair tissue Tartrate-Resistant Acid Phosphatase(TRAP) activity in adherent cell cultures was assessed using an acid phosphatase assay kit. Cells exhibiting TRAP-positive staining with three or more nuclei were identified as osteoclasts. The percentage of TRAP-positive cells was quantified by enumerating stained cells in a minimum of five randomly selected microscopic fields under light microscopy, calculated as: (Number of TRAP-positive cells ÷ Total cells per field) × 100%. ELISA Concentrations of TNF-α, IL-1β, IL-6, and IL-8 in cell culture supernatants were quantified using species-specific anti-mouse sandwich ELISA kits according to the manufacturer’s protocols. Western blot Total protein was extracted by adding 1 ml RIPA lysis buffer supplemented with protease inhibitors to 6-well plate cultures, followed by conventional SDS-PAGE. Proteins were transferred to PVDF membranes via semi-dry electrophoretic transfer, blocked with 5% skim milk, and incubated with primary antibody working solution at 4 °C overnight. After adding HRP-conjugated secondary antibody working solution for 1 h at room temperature, target bands were visualized using ECL chemiluminescent substrate. Antibody dilutions were: c-Fos (1:1500), NFATc1 (1:1500), Cathepsin K (1:1500), MMP-9 (1:1500), GAPDH (1:1500); HRP-IgG secondary antibody (1:5000). Analytics Quantification of markers from microscopic images was performed using ImageJ software.Statistical analysis employed GraphPad Prism version 8. Continuous data are presented as mean ± standard deviation (Mean ± SD). Student’s t-test compared differences between two groups; one-way analysis of variance (ANOVA) with Tukey’s post hoc test analyzed multiple group comparisons. Statistical significance was set at P < 0.05. Result Osteoclastogenesis-associated inflammatory factors are highly expressed in bone cyst tissue As detailed in Table 3, mRNA expression of osteoclastogenesis-associated inflammatory factors—TNF-α, IL-1β, IL-6, and IL-8—was significantly and consistently upregulated in bone cyst tissues compared to adjacent normal bone controls (all P < 0.01). The magnitude of increase was most pronounced for TNF-α and IL-1β. This robust transcriptional profile indicates a potent pro-inflammatory microenvironment within the cystic lesions, which is likely a major driver of pathological osteoclast activation.Table 3Statistical results of the determination of the expression of osteoclast differentiation-associated inflammatory factors in paracancerous bone tissues and bone cyst tissues Table (Mean ± SD)GroupTNF-α mRNA relative expression levelIL-1β mRNA relative expression levelIL-6 mRNA relative expression levelIL-8 mRNA relative expression levelAdjacent normal bone tissue(n = 21)1.00 ± 0.111.00 ± 0.131.00 ± 0.121.00 ± 0.16Bone Cyst Tissue (n = 21)37.52 ± 1.1128.44 ± 0.7617.36 ± 0.825.56 ± 0.45t150.00163.1090.4643.75P < 0.01 < 0.01 < 0.01 < 0.01 Table 3Statistical results of the determination of the expression of osteoclast differentiation-associated inflammatory factors in paracancerous bone tissues and bone cyst tissues Table (Mean ± SD)GroupTNF-α mRNA relative expression levelIL-1β mRNA relative expression levelIL-6 mRNA relative expression levelIL-8 mRNA relative expression levelAdjacent normal bone tissue(n = 21)1.00 ± 0.111.00 ± 0.131.00 ± 0.121.00 ± 0.16Bone Cyst Tissue (n = 21)37.52 ± 1.1128.44 ± 0.7617.36 ± 0.825.56 ± 0.45t150.00163.1090.4643.75P < 0.01 < 0.01 < 0.01 < 0.01 Statistical results of the determination of the expression of osteoclast differentiation-associated inflammatory factors in paracancerous bone tissues and bone cyst tissues Table (Mean ± SD) EgAgB enhances osteoclast differentiation in RAW 264.7 cells. As shown in Fig. 2 and Table 4 TRAP staining assays, significant increases in the percentage of TRAP-positive cells were observed in Induction + EgAgB: Concentration 1, 2, and 3 versus the Induction Group (P < 0.05); in Induction + EgAgB: Concentration 2 and 3 versus Concentration 1 (P < 0.05); and in Induction + EgAgB: Concentration 3 versus Concentration 2 (P < 0.05). Fig. 2TRAP staining of osteoclasts differentiated from RAW 264.7 cells treated with EgAgB. a Control group (RANKL induction only). b RANKL induction + 10 μg/mL EgAgB. c RANKL induction + 20 μg/mL EgAgB. d RANKL induction + 50 μg/mL EgAgB TRAP staining of osteoclasts differentiated from RAW 264.7 cells treated with EgAgB. a Control group (RANKL induction only). b RANKL induction + 10 μg/mL EgAgB. c RANKL induction + 20 μg/mL EgAgB. d RANKL induction + 50 μg/mL EgAgB Table 4Osteoclast differentiation quantified by TRAP staining. (Mean ± SD, n = 6)GroupPercentage of TRAP-positive Cells(%)Induction group22.0 ± 1.4aInduction + EgAgB: Concentration 141.4 ± 1.2bInduction + EgAgB: Concentration 257.8 ± 1.8cInduction + EgAgB: Concentration 383.2 ± 2.2d F 1405.00 P < 0.01Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. Values that do not share a common superscript letter (a, b, c, d) within the column are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Table 4Osteoclast differentiation quantified by TRAP staining. (Mean ± SD, n = 6)GroupPercentage of TRAP-positive Cells(%)Induction group22.0 ± 1.4aInduction + EgAgB: Concentration 141.4 ± 1.2bInduction + EgAgB: Concentration 257.8 ± 1.8cInduction + EgAgB: Concentration 383.2 ± 2.2d F 1405.00 P < 0.01Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. Values that do not share a common superscript letter (a, b, c, d) within the column are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Osteoclast differentiation quantified by TRAP staining. (Mean ± SD, n = 6) Data were analyzed by one-way ANOVA followed by Tukey’s post hoc test. Values that do not share a common superscript letter (a, b, c, d) within the column are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B EgAgB stimulation upregulates secretion of osteoclastogenesis-associated inflammatory factors in RAW 264.7 Cells As shown in Table 5, significantly elevated levels of TNF-α, IL-1β, IL-6, and IL-8 were observed in the Induction Group, Induction + EgAgB: Concentration 1, Concentration 2, and Concentration 3 compared to the Control Group (P < 0.05); furthermore, all three antigen concentration groups exhibited higher levels of these inflammatory factors versus the Induction Group alone (P < 0.05), with Concentrations 2 and 3 showing increased levels versus Concentration 1 (P < 0.05), and Concentration 3 demonstrating further elevation versus Concentration 2 (P < 0.05).Table 5Statistical results table for the measurement of levels of osteoclast differentiation-related inflammatory factors in the supernatant of RAW 264.7 cell cultures (Mean ± SD, n = 6)GroupTNF-α(ng/ml)IL-1β(ng/ml)IL-6(ng/ml)IL-8(ng/ml)Control Group16.47 ± 0.52a21.22 ± 0.43a31.33 ± 0.37a25.82 ± 0.32aInduction Group123.64 ± 1.11b56.53 ± 0.71b58.53 ± 0.42b61.23 ± 0.24bInduction + EgAgB: Concentration 1144.35 ± 1.34c88.45 ± 0.84c63.52 ± 0.53c66.37 ± 0.28cInduction + EgAgB: Concentration 2158.36 ± 1.41d95.76 ± 0.85d67.44 ± 0.56d70.12 ± 0.30dInduction + EgAgB: Concentration 3174.48 ± 1.55e102.34 ± 0.91e72.35 ± 0.61e73.46 ± 0.35eF15,319.0011,637.006065.0024,819.00P < 0.01 < 0.01 < 0.01 < 0.01Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Table 5Statistical results table for the measurement of levels of osteoclast differentiation-related inflammatory factors in the supernatant of RAW 264.7 cell cultures (Mean ± SD, n = 6)GroupTNF-α(ng/ml)IL-1β(ng/ml)IL-6(ng/ml)IL-8(ng/ml)Control Group16.47 ± 0.52a21.22 ± 0.43a31.33 ± 0.37a25.82 ± 0.32aInduction Group123.64 ± 1.11b56.53 ± 0.71b58.53 ± 0.42b61.23 ± 0.24bInduction + EgAgB: Concentration 1144.35 ± 1.34c88.45 ± 0.84c63.52 ± 0.53c66.37 ± 0.28cInduction + EgAgB: Concentration 2158.36 ± 1.41d95.76 ± 0.85d67.44 ± 0.56d70.12 ± 0.30dInduction + EgAgB: Concentration 3174.48 ± 1.55e102.34 ± 0.91e72.35 ± 0.61e73.46 ± 0.35eF15,319.0011,637.006065.0024,819.00P < 0.01 < 0.01 < 0.01 < 0.01Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Statistical results table for the measurement of levels of osteoclast differentiation-related inflammatory factors in the supernatant of RAW 264.7 cell cultures (Mean ± SD, n = 6) Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B EgAgB stimulation upregulates the c-Fos/NFATc1 signaling axis in RAW 264.7 cells As demonstrated in Fig. 3 and Table 6, significant upregulation of:(1) the key osteoclastogenic transcription factor axis c-Fos/NFATc1, and(2) the signature protease markers Cathepsin K and MMP-9— was observed in both the Induction Group and Induction + EgAgB: Concentration 3 Group compared to the Control Group (P < 0.05).Furthermore, Induction + EgAgB: Concentration 3 exhibited elevated expression of these markers versus the Induction Group alone (P < 0.05). Fig. 3Expression analysis of the key osteoclastogenic transcription factor axis c-Fos/NFATc1 in RAW 264.7 cells. Notes: a. Control group b. Induction group c. Induction + EgAgB: Concentration 3 Expression analysis of the key osteoclastogenic transcription factor axis c-Fos/NFATc1 in RAW 264.7 cells. Notes: a. Control group b. Induction group c. Induction + EgAgB: Concentration 3 Table 6Expression Analysis of the Key Osteoclastogenic Transcription Factor Axis c-Fos/NFATc1 in RAW 264.7 Cells (Mean ± SD, n = 6)Groupc-Fos relative expressionNFATc1 relative expressionCathepsin K relative expressionMMP9 relative expressionControl group1.00 ± 0.12a1.00 ± 0.10a1.00 ± 0.11a1.00 ± 0.10aInduction group1.72 ± 0.14b1.64 ± 0.12b2.12 ± 0.14b1.52 ± 0.13bInduction + EgAgB: concentration 32.23 ± 0.15c2.58 ± 0.16c2.87 ± 0.16c2.34 ± 0.14c F 121.70227.40278.20176.70 P < 0.01 < 0.01 < 0.01 < 0.01Notes:Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Table 6Expression Analysis of the Key Osteoclastogenic Transcription Factor Axis c-Fos/NFATc1 in RAW 264.7 Cells (Mean ± SD, n = 6)Groupc-Fos relative expressionNFATc1 relative expressionCathepsin K relative expressionMMP9 relative expressionControl group1.00 ± 0.12a1.00 ± 0.10a1.00 ± 0.11a1.00 ± 0.10aInduction group1.72 ± 0.14b1.64 ± 0.12b2.12 ± 0.14b1.52 ± 0.13bInduction + EgAgB: concentration 32.23 ± 0.15c2.58 ± 0.16c2.87 ± 0.16c2.34 ± 0.14c F 121.70227.40278.20176.70 P < 0.01 < 0.01 < 0.01 < 0.01Notes:Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Expression Analysis of the Key Osteoclastogenic Transcription Factor Axis c-Fos/NFATc1 in RAW 264.7 Cells (Mean ± SD, n = 6) Notes: Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B IL-1β antagonist downregulates c-Fos/NFATc1/Cathepsin K/MMP-9 expression in EgAgB-stimulated RAW 264.7 Cells As shown in Fig. 4 and Table 7,significant upregulation of:(1)the key osteoclastogenic transcription factor axis c-Fos/NFATc1,and(2)the signature proteases Cathepsin K and MMP-9—was observed in Induction + EgAgB:Concentration 3 versus the Induction Group (P < 0.05).Conversely, Induction + EgAgB: Concentration 3 + IL-1βAntagonist showed marked downregulation of these markers compared to Induction + EgAgB: Concentration 3 (P < 0.05). Fig. 4Expression levels of c-Fos/NFATc1/Cathepsin K/MMP-9 in RAW 264.7 Cells. Notes: 1. Control Group, 2. Induction Group, 3. Induction + EgAgB: Concentration 3, 4. Induction + EgAgB: Concentration 3 + IL-1β Antagonist Expression levels of c-Fos/NFATc1/Cathepsin K/MMP-9 in RAW 264.7 Cells. Notes: 1. Control Group, 2. Induction Group, 3. Induction + EgAgB: Concentration 3, 4. Induction + EgAgB: Concentration 3 + IL-1β Antagonist Table 7Statistical analysis of c-Fos/NFATc1/Cathepsin K/MMP-9 expression levels in RAW 264.7 cells(Mean ± SD, n = 6)Groupc-Fos relative expressionNFATc1 relative expressionCathepsin K relative expressionMMP9 relative expressionControl group1.00 ± 0.12a1.00 ± 0.11a1.00 ± 0.10a1.00 ± 0.12aInduction group1.75 ± 0.14b1.66 ± 0.12b2.10 ± 0.12b1.55 ± 0.14bInduction + EgAgB: Concentration 32.36 ± 0.13c2.41 ± 0.14c2.45 ± 0.14c2.67 ± 0.21cInduction + EgAgB:Concentration 3 + IL-1β Antagonist1.78 ± 0.11b1.65 ± 0.13b2.08 ± 0.11b1.57 ± 0.13b F 118.40126.60168.90123.80 P < 0.01 < 0.01 < 0.01 < 0.01Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Table 7Statistical analysis of c-Fos/NFATc1/Cathepsin K/MMP-9 expression levels in RAW 264.7 cells(Mean ± SD, n = 6)Groupc-Fos relative expressionNFATc1 relative expressionCathepsin K relative expressionMMP9 relative expressionControl group1.00 ± 0.12a1.00 ± 0.11a1.00 ± 0.10a1.00 ± 0.12aInduction group1.75 ± 0.14b1.66 ± 0.12b2.10 ± 0.12b1.55 ± 0.14bInduction + EgAgB: Concentration 32.36 ± 0.13c2.41 ± 0.14c2.45 ± 0.14c2.67 ± 0.21cInduction + EgAgB:Concentration 3 + IL-1β Antagonist1.78 ± 0.11b1.65 ± 0.13b2.08 ± 0.11b1.57 ± 0.13b F 118.40126.60168.90123.80 P < 0.01 < 0.01 < 0.01 < 0.01Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Statistical analysis of c-Fos/NFATc1/Cathepsin K/MMP-9 expression levels in RAW 264.7 cells(Mean ± SD, n = 6) Data are presented as the mean ± SD (n = 6). One-way ANOVA with Tukey’s post hoc test was performed for statistical analysis. Within each column, values that do not share a common superscript letter are significantly different (P < 0.05). EgAgB, Echinococcus granulosus Antigen B Discussion Increased osteoclast (OC) differentiation and activity are key events driving bone loss and joint destruction. OCs are multinucleated cells with three or more nuclei, typically located on trabecular bone surfaces. Their cytoplasm contains high concentrations of vesicles and vacuoles filled with lysosomal acid phosphatase [stained by tartrate-resistant acid phosphatase (TRAP)] and cathepsin K [16]. Activated OCs are characterized by forming a specialized cell membrane called the ruffled border, which opposes the bone surface and facilitates the secretion of acids and lysosomal enzymes for bone resorption [17]. Concurrently, these cells exhibit elevated expression of matrix metalloproteinases (MMPs) 8 and 9 [18]. Receptor activator of nuclear factor-kappa B ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily, binds to its receptor RANK. In conjunction with macrophage colony-stimulating factor (M-CSF) stimulation, the RANKL-RANK interaction induces terminal differentiation, fusion, and activation of osteoclasts (OCs) [14]. However, RANK lacks intrinsic kinase activity to mediate downstream signaling; consequently, RANKL binding recruits various molecules, including TNF receptor-associated factors (TRAFs) and kinases, such as transforming growth factor-β-activated kinase 1 (TAK1). This recruitment subsequently activates the transcription factors NF-κB, c-Fos, and nuclear factor of activated T cells cytoplasmic 1 (NFATc1), all of which are essential for OC differentiation [19].Our results demonstrated that hydatid antigen B protein enhanced RANKL- and M-CSF-induced osteoclast differentiation of RAW 264.7 cells in a concentration-dependent manner. This was evidenced by a significant increase in the percentage of TRAP⁺ cells in the high-dose antigen B group compared to the medium-dose group. Proinflammatory cytokines, including TNF-α, IL-1β, IL-6, and IL-8, can activate the differentiation of osteoclast precursors into osteoclasts (OCs) [13]. Similar to, yet independently of RANKL, TNF-α recruits TNF receptor-associated factors (TRAFs), subsequently activating the transcription factors NF-κB, c-Fos, and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) to induce OC differentiation [19]. A study by Ma et al. demonstrated that inhibition of G protein-coupled receptor 120 (GPR120) suppresses TNF-α-activated osteoclast differentiation (Ma et al., 2023) [20]. IL-6 and TNF-α synergistically activate osteocyte-mediated OC differentiation and activation, mediating the pathological progression of osteoimmunology through complex mechanisms in rheumatoid arthritis and postmenopausal osteoporosis [21]. The IL-6/RANKL axis is crucial for osteocyte-mediated activation of OC differentiation [22]. Elevated levels of IL-8 promote breast cancer bone metastasis, and inhibition of IL-8 suppresses this pathological process [23].Compared to the induction group alone, stimulation with a high dose of hydatid antigen B further potentiated the activation of the c-Fos/NFATc1 signaling axis in RAW 264.7 cells. IL-1β is another critical proinflammatory cytokine that plays a pivotal role in pathological bone erosion. It enhances NF-κB-mediated osteoclast (OC) differentiation through mechanisms independent of both RANKL and TRAF6. IL-1β activates OC differentiation and bone resorption in a PKCθ/NF-κB/IL-1β-Dependent positive feedback loop [24]. Treatment with IL-1β upregulates the expression of inducible nitric oxide synthase (iNOS), insulin-like growth factor 2 (IGF-2), and chemokines CX3CL1 and CXCL7 in mouse bone marrow stem cells, thereby promoting the differentiation of non-osteoclastic cells into OCs during bone erosion in rheumatoid arthritis [25]. The NLRP3 inflammasome accelerates osteolysis and bone remodeling in osteoporosis by upregulating IL-1β, whereas blockade of the NLRP3/IL-1β signaling axis attenuates this pathological process [26]. After entering bone tissue, CE cysts fail to elicit a typical demarcating reactive fibrous capsule from the host. Instead, CE invades adjacent bone regions in a manner analogous to bone tumors [2]. On computed tomography (CT) scans, CE-induced skeletal destruction exhibits a “moth-eaten” pattern, with lesional areas demonstrating a “rat-bite” morphological appearance [27]. CE enhances osteolytic bone erosion by activating osteoclasts (OCs) through Nrf2-mediated suppression, which elevates oxidative stress and inflammation at bone resorption surfaces [28]. Tissues surrounding CE-induced bone erosions show heightened inflammation, dysregulated osteoimmune responses, and abnormally elevated OC activity [29]. Notably, the molecular mechanisms underlying this dysregulation are being rapidly uncovered. Recent studies have identified that E. granulosus infection can promote osteoclastogenesis through the DUSP4-MAPK signaling axis [10], and very recently, Liu et al. (2025) demonstrated a pivotal pathway via the inhibition of Nrf2, leading to ROS accumulation and MAPK pathway activation, which converges on the upregulation of c-Fos and NFATc1 [3].Following CE infection, patients test positive for antibodies against E. granulosus cyst fluid (EgCF), E. granulosus protoscolex (EgP), and semi-purified hydatid cyst fluid native antigen B (EgB).In the current study, analysis of mRNA expression levels for osteoclast differentiation-associated inflammatory factors in CE bone cyst tissues revealed elevated relative expression of TNF-α, IL-1β, IL-6, and IL-8 compared to adjacent non-lesioned bone tissue. Stimulation with hydatid antigen B protein upregulated secretion of osteoclastogenic inflammatory factors (TNF-α, IL-1β, IL-6, IL-8) in RAW 264.7 cells and enhanced their differentiation into osteoclasts, concurrently increasing intracellular expression of c-Fos, NFATc1, Cathepsin K, and MMP-9. Treatment with an IL-1β antagonist suppressed hydatid antigen B-induced expression of c-Fos, NFATc1, Cathepsin K, and MMP-9 in RAW 264.7 cells. Our discovery of the IL-1β/c-Fos/NFATc1 axis therefore reveals a novel, cytokine-driven mechanism complementary to the recently identified Nrf2/ROS/MAPK [3] and DUSP4-MAPK [10] pathways, collectively illustrating the multi-faceted strategy employed by the parasite to drive osteolysis.These findings suggest that IL-1β antagonism may inhibit pathological osteolytic destruction in skeletal CE.This finding holds significant novelty as, to our knowledge, no prior studies have investigated the therapeutic potential of IL-1β antagonism, specifically using canakinumab, for mitigating pathological osteolysis in skeletal CE.This suggests that the current therapeutic paradigm, primarily focused on pathogen eradication with albendazole, should be expanded to include host-directed adjunctive strategies that disrupt the maladaptive immuno-inflammatory response driving progressive osteolysis.The identification of these distinct yet convergent pathways, including IL-1β (this study), Nrf2 [3], and DUSP4 [10], highlights several promising therapeutic nodes for combination therapy with albendazole. Collectively, while this study has not delineated whether TNF-α or IL-1β plays a predominant role—or whether they act synergistically—in pathological osteolytic destruction during CE infection, our findings establish that Echinococcus granulosus infection promotes osteoclast differentiation and activation in osseous CE through the IL-1β/c-Fos/NFATc1 signaling axis. However, a primary limitation of this study lies in its reliance on an in vitro murine cell line model, which, although powerful for mechanistic investigation, cannot fully recapitulate the complex host–parasite interactions and bone microenvironment of human disease. Therefore, future studies should prioritize validation of these findings using an in vivo preclinical animal model of osseous CE and investigate the combined efficacy of anti–IL-1β therapy with standard albendazole treatment.